These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36456428)
21. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study. Liu QP; Yang KL; Xu X; Liu XS; Qu JR; Zhang YD Abdom Radiol (NY); 2022 Feb; 47(2):651-663. PubMed ID: 34918174 [TBL] [Abstract][Full Text] [Related]
22. Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma. Zhao Y; Wang N; Wu J; Zhang Q; Lin T; Yao Y; Chen Z; Wang M; Sheng L; Liu J; Song Q; Wang F; An X; Guo Y; Li X; Wu T; Liu AL Front Oncol; 2021; 11():582788. PubMed ID: 33868988 [TBL] [Abstract][Full Text] [Related]
23. Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Deng K; Chen T; Leng Z; Yang F; Lu T; Cao J; Pan W; Zheng Y Radiol Med; 2024 Aug; 129(8):1099-1117. PubMed ID: 39060885 [TBL] [Abstract][Full Text] [Related]
24. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Sheen H; Kim JS; Lee JK; Choi SY; Baek SY; Kim JY Abdom Radiol (NY); 2021 Jun; 46(6):2839-2849. PubMed ID: 33388805 [TBL] [Abstract][Full Text] [Related]
25. An interpretable machine learning model based on contrast-enhanced CT parameters for predicting treatment response to conventional transarterial chemoembolization in patients with hepatocellular carcinoma. Zhang L; Jin Z; Li C; He Z; Zhang B; Chen Q; You J; Ma X; Shen H; Wang F; Wu L; Ma C; Zhang S Radiol Med; 2024 Mar; 129(3):353-367. PubMed ID: 38353864 [TBL] [Abstract][Full Text] [Related]
26. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680 [No Abstract] [Full Text] [Related]
27. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874 [TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. He CB; Lao XM; Lin XJ Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568 [TBL] [Abstract][Full Text] [Related]
29. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging. Byun J; Kim SY; Kim JH; Kim MJ; Yoo C; Shim JH; Lee SS Acta Radiol; 2021 Dec; 62(12):1548-1558. PubMed ID: 33197329 [TBL] [Abstract][Full Text] [Related]
30. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. Sun Y; Bai H; Xia W; Wang D; Zhou B; Zhao X; Yang G; Xu L; Zhang W; Liu P; Xu J; Meng S; Liu R; Gao X J Magn Reson Imaging; 2020 Oct; 52(4):1083-1090. PubMed ID: 32233054 [TBL] [Abstract][Full Text] [Related]
31. Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos. Zhang L; Jiang Y; Jin Z; Jiang W; Zhang B; Wang C; Wu L; Chen L; Chen Q; Liu S; You J; Mo X; Liu J; Xiong Z; Huang T; Yang L; Wan X; Wen G; Han XG; Fan W; Zhang S Cancer Imaging; 2022 May; 22(1):23. PubMed ID: 35549776 [TBL] [Abstract][Full Text] [Related]
32. Development of a novel combined nomogram model integrating Rad-score, age and ECOG to predict the survival of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Liu A; Liu B; Duan X; Yang B; Wang Y; Dong P; Zhou P J Gastrointest Oncol; 2022 Aug; 13(4):1889-1897. PubMed ID: 36092317 [TBL] [Abstract][Full Text] [Related]
33. Application of Radiomics in the Efficacy Evaluation of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Wang Y; Li M; Zhang Z; Gao M; Zhao L Acad Radiol; 2024 Jan; 31(1):273-285. PubMed ID: 37684182 [TBL] [Abstract][Full Text] [Related]
34. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694 [TBL] [Abstract][Full Text] [Related]
35. Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma. Fan XL; Wang YH; Chen YH; Chen BX; Cai JN; Yang JS; Sun X; Yan FR; He BS Abdom Radiol (NY); 2023 Jun; 48(6):2008-2018. PubMed ID: 36943423 [TBL] [Abstract][Full Text] [Related]
36. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization. Jia F; Wu B; Yan R; Li L; Wang K; Han D J Magn Reson Imaging; 2020 Dec; 52(6):1657-1667. PubMed ID: 32424881 [TBL] [Abstract][Full Text] [Related]
37. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299 [TBL] [Abstract][Full Text] [Related]
38. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Sheng Y; Wang Q; Liu HF; Chen WH; He ZM; Wang Q Acad Radiol; 2023 Jul; 30(7):1288-1297. PubMed ID: 36424310 [TBL] [Abstract][Full Text] [Related]
39. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Li L; Kan X; Zhao Y; Liang B; Ye T; Yang L; Zheng C Int J Med Sci; 2021; 18(11):2276-2284. PubMed ID: 33967603 [No Abstract] [Full Text] [Related]
40. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]